Candida auris fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023

After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of -related invasive infections has been observed globally. However, the contemporary epidemiology of fungaemias in Greece remains unknown. An outbreak of bloodstream infections has been ongoing for...

Full description

Saved in:
Bibliographic Details
Published in:Euro surveillance : bulletin européen sur les maladies transmissibles 2024-11, Vol.29 (45), p.1
Main Authors: Meletiadis, Joseph, Siopi, Maria, Spruijtenburg, Bram, Georgiou, Panagiota-Christina, Kostoula, Maria, Vourli, Sophia, Frantzeskaki, Frantzeska, Paramythiotou, Elisabeth, Meis, Jacques F, Tsangaris, Iraklis, Pournaras, Spyros
Format: Article
Language:English
Subjects:
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Candida auris - drug effects
Candida auris - genetics
Candidemia - drug therapy
Candidemia - epidemiology
Candidemia - microbiology
Candidiasis - drug therapy
Candidiasis - epidemiology
Candidiasis - microbiology
COVID-19 - epidemiology
Cross Infection - drug therapy
Cross Infection - epidemiology
Cross Infection - microbiology
Disease Outbreaks
Drug Resistance, Fungal
Echinocandins - pharmacology
Echinocandins - therapeutic use
Epidemiology
Female
Fungal infections
Greece - epidemiology
Hospitalization
Humans
Male
Microbial Sensitivity Tests
Outbreaks
Pandemics
Public health
SARS-CoV-2
Tertiary Care Centers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After the start of the COVID-19 pandemic, a rapid rise in reported numbers and wide geographic spread of -related invasive infections has been observed globally. However, the contemporary epidemiology of fungaemias in Greece remains unknown. An outbreak of bloodstream infections has been ongoing for almost 3 years in a Greek tertiary care academic hospital, with 89 -driven episodes appearing in five waves every 6-7 months following peaks in colonisation rates by 3-4 months. All isolates clustered in clade I and were genetically related, 84% were fluconazole-resistant and all were non-resistant to amphotericin B and echinocandins, except one pan-echinocandin-resistant isolate ( mutant) recovered from a patient on empiric therapy with anidulafungin. Notably, was in 2023 the most prevalent (34%) cause of candidaemia in our hospital. The accelerated and long-term transmission dynamics of fungaemia underscore the need for rigorous infection control measures, while antifungal stewardship is warranted to contain the selection of echinocandin-resistant isolates.
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2024.29.45.2400128